Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion

L. N. Maslov, Yu B. Lishmanov, J. P. Headrick, J. M. Pei, L. Hanuš, A. V. Krylatov, N. V. Naryzhnaya

Результат исследований: Материалы для журналаСтатья

2 Цитирования (Scopus)

Выдержка

It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

Язык оригиналаАнглийский
Страницы (с-по)22-28
Число страниц7
ЖурналEksperimental'naya i Klinicheskaya Farmakologiya
Том75
Номер выпуска10
СостояниеОпубликовано - 2012

Отпечаток

Opioid Receptors
Opioid Analgesics
Reperfusion
Ischemia
Pharmaceutical Preparations
Odds Ratio
Cardiac Myocytes
Chemical activation
Apoptosis

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Цитировать

Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion. / Maslov, L. N.; Lishmanov, Yu B.; Headrick, J. P.; Pei, J. M.; Hanuš, L.; Krylatov, A. V.; Naryzhnaya, N. V.

В: Eksperimental'naya i Klinicheskaya Farmakologiya, Том 75, № 10, 2012, стр. 22-28.

Результат исследований: Материалы для журналаСтатья

Maslov, L. N. ; Lishmanov, Yu B. ; Headrick, J. P. ; Pei, J. M. ; Hanuš, L. ; Krylatov, A. V. ; Naryzhnaya, N. V. / Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion. В: Eksperimental'naya i Klinicheskaya Farmakologiya. 2012 ; Том 75, № 10. стр. 22-28.
@article{01959fd44e464efc85bb176c35b96599,
title = "Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion",
abstract = "It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.",
keywords = "Heart, Ischemia, Opioid receptor ligands, Reperfusion",
author = "Maslov, {L. N.} and Lishmanov, {Yu B.} and Headrick, {J. P.} and Pei, {J. M.} and L. Hanuš and Krylatov, {A. V.} and Naryzhnaya, {N. V.}",
year = "2012",
language = "English",
volume = "75",
pages = "22--28",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "10",

}

TY - JOUR

T1 - Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion

AU - Maslov, L. N.

AU - Lishmanov, Yu B.

AU - Headrick, J. P.

AU - Pei, J. M.

AU - Hanuš, L.

AU - Krylatov, A. V.

AU - Naryzhnaya, N. V.

PY - 2012

Y1 - 2012

N2 - It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

AB - It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

KW - Heart

KW - Ischemia

KW - Opioid receptor ligands

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84871522974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871522974&partnerID=8YFLogxK

M3 - Article

C2 - 23240155

AN - SCOPUS:84871522974

VL - 75

SP - 22

EP - 28

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 10

ER -